Merck KGaA has acquired Bangalore Genei (India) Private in a deal which it says will help it become one of the leading bioscience companies the country.

The Germany-based firm’s wholly-owned Indian subsidiary, Merck Specialities Private, has bought BGIP from the Sanmar Group, though financial details have not been disclosed. BGIP, which has more than 100 employees, specialises in products for proteomic and genomic research, and generated revenues of 202 million rupees (around 3.0 million euros) in fiscal year 2008/09.

Christina Shasserre, global head of Merck's bioscience business, said that “BGIP’s leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base”. He added that the newly-acquired firm’s product portfolio “comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India”.